Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?-Reference-Cited by-同舟云学术

Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?

Published:2013-11-22 Issue:1 Volume:39 Page:61-68
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Park I.-W.¹,Sheen S. S.²,Yoon D.³,Lee S.-H.⁴,Shin G.-T.¹,Kim H.¹,Park R. W.³⁵⁶

Affiliation:

1. Department of Nephrology; Ajou University School of Medicine; Suwon Korea

2. Department of Pulmonary and Critical Care Medicine; Ajou University School of Medicine; Suwon Korea

3. Department of Biomedical Informatics; Ajou University School of Medicine; Suwon Korea

4. College of Pharmacy; Ajou University; Suwon Korea

5. Center for Clinical Epidemiology; and Biostatistics, and Department of Biostatistics & Epidemiology; Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA

6. Center for Pharmacoepidemiololgy Research and Training; Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA

Funder

National Research Foundation of Korea

Korea government

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12109/fullpdf

Reference28 articles.

1. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006;Hemmelgarn;Can J Cardiol,2008

2. Angiotensin receptor blockers: pharmacology, efficacy, and safety;Taylor;J Clin Hypertens (Greenwich),2011

3. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors;Granger;Am Heart J,2000

4. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers;Raebel;Cardiovasc Ther,2012

5. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers;Sadjadi;Ther Clin Risk Manag,2009

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Reactions in Renal Function and Electrolytes Associated with Antihypertensive and Antidiabetic Therapy;Blood Pressure Disorders in Diabetes Mellitus;2023

2. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity;The American Journal of Medicine;2022-12

3. Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis;European Journal of Hospital Pharmacy;2021-06-28

4. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker;Cardiovascular Therapeutics;2021-01-22

5. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations;Circulation: Cardiovascular Quality and Outcomes;2020-09